Why H.S.A. Is Losing Its Grip on the Male Genitalia
H.A., the company that has made the penis-shaped penis the standard of its line of products, has gone into an all-out retreat on erectile function.
It announced last month that it had hired a global research firm to conduct a study on how erectile problems affect men, and on what the firm found.
It also announced that it was taking a long look at what men can do to combat H. A.D.D., and it plans to make changes to the way it sells its products.
H.I.V. tests will also be made optional for men to take in the future.
But H. S.A.’s new leadership will not be making much headway on erecting a more attractive and healthier penis.
The company’s board of directors, including CEO Jim Rogers, voted to hire a new CEO on Wednesday, and the chairman and chief executive of the company’s global health division, Dr. James F. McQuillan, resigned.
“There is still a lot of work to do to get to the top, to make the most of what we have, said Dr. John B. Cogan, the vice chairman of the board.
H.S., which is based in Palo Alto, Calif., has been one of the largest players in erectile health and treatment since the 1970s, when its founder, Charles E. Wilson, first developed an erectile-dysfunction drug.
It has expanded its offerings to include erectile prosthetics and implants, including one made by British company, OrthoElectro.
However, the company, which is now valued at $1.6 billion, has also struggled to adapt to changing medical and technological needs.
Its chief financial officer, Dr